Resistance profiles of cyclic and linear inhibitors of HIV-1 protease

Antiviral Chemistry and Chemotherapy

Volumn 13, Issue 1, 2002, Pages 27-37

  Ahlsen G ^a   Hulten J ^a   Shuman, C F ^a   Poliakov, A ^a   Lindgren, M T ^a   Alterman, M ^a   Samuelsson, B ^b   Hallberg, A ^a   Danielson, U H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

Cyclic sulfamide; HIV 1 protease; Inhibition; Kinetics; Resistance; Vitality

Indexed keywords

PROTEINASE INHIBITOR; SULFANILAMIDE; UREA DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TREATMENT PLANNING; VIRUS RESISTANCE;

EID: 0036462258     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020201300103     Document Type: Article

References (37)

1. Ala PJ, Huston EE, Klabe RM, McCabe DD, Duke JL, Rizzo CJ, Korant BD, DeLoskey RJ, Lam PY, Hodge CN & Chang CH (1997). Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36:1573-1580.
2. Alterman M, Björsne M, Muhlman A, Classon B, Kvarnström I, Danielson H, Markgren P-O, Nillroth U, Unge T, Hallberg A & Samuelsson B (1998). Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. Journal of Medicinal Chemistry 41:3782-3792.
3. Alterman M, Andersson HO, Garg N, Ahlsén G, Lövgren S, Classon B, Danielson UH, Kvarnström I, Vrang L, Unge T, Samuelsson B & Hallberg A (1999). Design and fast synthesis of C-terminal duplicated potent C2-symmetric P1/P1′-modified HIV-1 protease inhibitors. Journal of Medicinal Chemistry 42:3835-3844.
4. Bäckbro K, Löwgren S, Österlund K, Atepo J, Unge T, Hultén J, Bonham NM, Schaal W, Karlén A & Hallberg A (1997). Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. Journal of Medicinal Chemistry 40:898-902.
5. Cabana M, Clotet B & Martinez MA (1999). Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. Journal of Medical Virology 59:480-490.
6. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M & Emini EA (2000). Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy. Journal of Infectious Diseases 182:758-765.
7. Craig C, Race E, Sheldon J, Whittaker L, Gilbert S, Moffatt A, Rose J, Dissanayeke S, Chirn GW, Duncan IB & Cammack N (1998). HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 12:1611-1618.
8. Danielson H, Lindgren MT, Markgren PO & Nillroth U (1998). Investigation of an allosteric site of HIV-1 proteinase involved in inhibition by Cu2+. Advances in Experimental Medicine and Biology 436:99-103.
9. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L & Lamarre D (1996). Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. Journal of Virology 70:3763-3769.
10. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R & Richman DD (2000). 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Annals of Internal Medicine 133:35-39.
11. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H & Erickson JW (1995). Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287.
12. Hodge CN, Aldrich PE, Bacheler LT, Chang CH, Eyermann CJ, Garber S, Grubb M, Jackson DA, Jadhav PK, Korant B, Lam PY, Maurin MB, Meek JL, Otto MJ, Rayner MM, Reid C, Sharpe TR, Shum L, Winslow DL & Erickson-Viitanen S (1996). Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chemistry and Biology 3:301-314.
13. Hong L, Zhang XJ, Foundling S, Hartsuck JA & Tang J (1997). Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs. FEBS Letters 420:11-16.
14. Hultén J, Bonham NM, Nillroth U, Hansson T, Zuccarello G, Bouzide A, Aqvist J, Classon B, Danielson UH, Karlén A, Kvarnström I, Samuelsson B & Hallberg A (1997). Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding afinities. Journal of Medicinal Chemistry 40:885-897.
15. Hultén J, Andersson HO, Schaal W, Danielson UH, Classon B, Kvarnström I, Karlén A, Unge T, Samuelsson B & Hallberg A (1999). Inhibitors of the C2-symmetric HIV-1 protease: Nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2′ side chains. Journal of Medicinal Chemistry 42:4054-4061.
16. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Kröhn A, Duncan IB & Mous J (1995). Characterization of human immunodeficiency virus type 1 protease mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
17. Jacobsen H, Hanggi M, Ott M, Duncan IB, Owen S, Andreoni M, Vella S & Mous J (1996). In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. Journal of Infectious Diseases 173:1379-1387.
18. Jadhav PK, Ala P, Woerner FJ, Chang C-H, Garber SS, Anton ED & Bacheler LT (1997). Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. Journal of Medicinal Chemistry 40:181-191.
19. King RW, Winslow DL, Garber S, Scarnati HT, Bachelor L, Stack S & Otto MJ (1995). Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. Antiviral Research 28:13-24.
20. Koch N, Yahi N, Arasi F, Fantini J & Tamalet C (1999). Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients recieving combination drug therapy. Journal of Clinical Microbiology 37:1595-1597.
21. Lam PYS, Jadhav PK, Eyermann CJ, Hodge N, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong N, Chang C-H, Weber PC, Jackson DA, Sharpe TR & Erickson-Viitanen S (1994). Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263:380-384.
22. Lam PYS, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang C-H, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Jackson DA, Erickson-Viitanen S, & Hodge CN (1996). Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. Journal of Medicinal Chemistry 39:3514-3525.
23. Mahalingam B, Louis JM, Reed CC, Adomat JM, Krouse J, Wang YF, Harrison RW & Weber IT (1999). Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. European Journal of Biochemistry 263:238-245.
24. Markgren P-O, Lindgren M, Gertow K, Karlsson R, Hämäläinen M & Danielson UH (2001). Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Analytical Biochemistry 291:207-218.
25. Nillroth U, Vrang L, Markgren P-O, Hultén J, Hallberg A & Danielson UH (1997). Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs. Antimicrobial agents and chemotherapy 41:2383-2388.
26. Olsen DB, Stalhut MW, Rutkowski CA, Schock HB, van Olden AL & Kuo LC (1999). Non-active site changes elicit broad-based cross resistance of the HIV-1 protease to inhibitors. Journal of Biological Chemistry 34:23699-23701.
27. Palmer S, Schafer RW & Merigan T (1999). Highly drug-resistant HIV-1 clinical isolates are cross resistant to many antiretroviral compounds in current clinical development. AIDS 13:661-667.
28. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, Stuver CM, Byrn RA & Livingston DJ (1995). In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. Journal of Virology 69:5228-5235.
29. Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kurtizkes DR & Markowitz M (1998). Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents and Chemotherapy 42:2637-2644.
30. 2-symmetric diol-based HIV-1 protease inhibitors. Effects of fluoro substitution. Journal of Medicinal Chemistry 44:3083-3091.
31. Richman DD (2001). HIV chemotherapy. Nature 410:995-1001.
32. Ridky TW, Kikonyogo A, Leis J, Gulnik S, Copeland T, Erickson J, Wlodawer A, Kurinov I, Harrison RW & Weber IT (1998). Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37:13835-13845.
33. Rodgers JD, Lam PY, Johnson BL, Wang H, Li R, Ru Y, Ko SS, Seitz SP, Trainor GL, Anderson PS, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Wright MR, Chang CH & Erickson-Viitanen S (1998). Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. Chemistry and Biology 10:597-608.
34. Schaal W, Karlsson A, Ahlsén G, Lindberg J, Andersson HO, Danielson UH, Classon B, Unge T, Samuelsson B, Hultén J, Hallberg A & Karlén A (2001). Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. Journal of Medicinal Chemistry 44:155-169.
35. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S & Stevenson M (2000). Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nature Medicine 6:76-81.
36. Tomasselli AG & Heinrikson RL (2000). Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochimica et Biophysica Acta 1477:189-214.
37. Wlodawer A & Vondrasek J (1998). Inhibitors of HIV-1 protease: a major success of structure assisted drug design. Annual Review of Biophysics and Biomolecular Structure 27:249-284.